Lawrence C. Parish
Expertise in
28
conditions

Dr. Lawrence C. Parish

Dermatology
1845 Walnut Street, Suite 1650, 
Philadelphia, PA 
Accepting New Patients
Expertise in
28
conditions
1845 Walnut Street, Suite 1650, 
Philadelphia, PA 

Overview

Lawrence Parish is a Dermatologist practicing medicine in Philadelphia, Pennsylvania.

Dr. Parish is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Hartnup Disease, Athlete's Foot, Contact Dermatitis, and Pellagra.

Dr. Parish is board certified in American Board Of Dermatology. He is actively involved in clinical research, co-authoring 188 peer reviewed articles and participating in 12 clinical trials. Dr. Parish is currently accepting new patients.

Specialties

Dermatology

Licenses

Dermatology in PA

Board Certifications

American Board Of Dermatology

Hospital Affiliations

Mercy Fitzgerald Hospital
Nazareth Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Parish Dermatology
1845 Walnut Street, Suite 1650, Philadelphia, PA 19103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
Enrollment Status: Completed
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drug: GSK1070806
Study Phase: Phase 1
A Single Treatment Pharmacokinetic and Safety Study of Natroba (Spinosad) Topical Suspension 0.9% w/w in Subjects 1 Month to 3 Years 11 Months of Age With an Active Scabies Infestation
A Single Treatment Pharmacokinetic and Safety Study of Natroba (Spinosad) Topical Suspension 0.9% w/w in Subjects 1 Month to 3 Years 11 Months of Age With an Active Scabies Infestation
Enrollment Status: Unknown
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 4
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 1
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: NKTR-358
Study Phase: Phase 1
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Multiple Intravenous Doses of FB825 in Adults With Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Multiple Intravenous Doses of FB825 in Adults With Atopic Dermatitis
Enrollment Status: Unknown
Publish Date: April 04, 2022
Intervention Type: Biological, Other
Study Drug: FB825
Study Phase: Phase 2
A Phase I/II Clinical Trial of Topical KB105, a Replication-incompetent, Non-integrating HSV-1 Vector Expressing Human Transglutaminase 1 (TGM1) for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)
A Phase I/II Clinical Trial of Topical KB105, a Replication-incompetent, Non-integrating HSV-1 Vector Expressing Human Transglutaminase 1 (TGM1) for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)
Enrollment Status: Unknown
Publish Date: September 13, 2021
Intervention Type: Biological
Study Drug: KB105
Study Phase: Phase 1/Phase 2
Open-Label Study of the Pharmacokinetics and Safety Including HPA Axis Suppression Potential of Clobetasol Topical Oil in Pediatric Subjects With Moderate to Severe Atopic Dermatitis
Open-Label Study of the Pharmacokinetics and Safety Including HPA Axis Suppression Potential of Clobetasol Topical Oil in Pediatric Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: June 23, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

188 Total Publications

The Dermatologist can be a Main Character in Non-Medical Books: A Succinct Review of Fiction Novels, Including a Summary about their Authors, in which a Dermatologist is either the Protagonist, Antagonist, or Deuteragonist.
The Dermatologist can be a Main Character in Non-Medical Books: A Succinct Review of Fiction Novels, Including a Summary about their Authors, in which a Dermatologist is either the Protagonist, Antagonist, or Deuteragonist.
Journal: Clinics in dermatology
Published: August 08, 2026
Similar Doctors
Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

Penn Dermatology Perelman

3400 Civic Center Boulevard, South Pavilion, 1st Floor, 
Philadelphia, PA 
 (1.2 miles away)
215-662-2737
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Victoria Werth, MD is a Dermatologist in Philadelphia, PA and has over 42 years of experience in the medical field. She graduated from Johns Hopkins School of Medicine in 1980. She is affiliated with Hospital of the University of Pennsylvania. Dr. Werth is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Cutaneous Lupus Erythematosus (CLE), Dermatomyositis, Discoid Lupus Erythematosus (DLE), and Pemphigus. Dr. Werth is board certified in Dermatology - Dermatopathology, 1989, Dermatology, 1986, and Internal Medicine, 1983.

Expertise in
26
conditions
Expertise in
26
conditions
Referral required
Before you request

Penn Dermatology Perelman

3400 Civic Center Boulevard, South Pavilion, 1st Floor, 
Philadelphia, PA 
 (1.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Micheletti is a Dermatologist practicing medicine in Philadelphia, Pennsylvania. Dr. Micheletti is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Acute Febrile Neutrophilic Dermatosis, Hidradenitis Suppurativa, Calciphylaxis, and Pyoderma Gangrenosum. Dr. Micheletti is board certified in Dermatology, 2013. Dr. Micheletti is currently accepting new patients.

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required
Before you request

Penn Dermatology Perelman

3400 Civic Center Boulevard, South Pavilion, 1st Floor, 
Philadelphia, PA 
 (1.2 miles away)
215-662-2737
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Misha Rosenbach is a Dermatologist practicing medicine in Philadelphia, Pennsylvania. Dr. Rosenbach is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Granuloma Annulare, Acute Febrile Neutrophilic Dermatosis, Sarcoidosis, and Pyoderma Gangrenosum. Dr. Rosenbach is board certified in Dermatology, 2009. Dr. Rosenbach is currently accepting new patients.

Frequently Asked Questions about Dr. Lawrence C. Parish

How do I make an appointment with Dr. Lawrence C. Parish?

You can book an appointment with Dr. Lawrence C. Parish by calling their office at 215-563-8333. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lawrence C. Parish a top-rated expert for Hartnup Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lawrence C. Parish is classified as an Distinguished expert for Hartnup Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lawrence C. Parish specialize in?

While Dr. Lawrence C. Parish is a Dermatology, they have specific expertise in Hartnup Disease, Athlete's Foot, and Contact Dermatitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Lawrence C. Parish participate in research or clinical trials?

Yes. Dr. Lawrence C. Parish has published 188 articles and abstracts on conditions like Hartnup Disease. You can view a list of Dr. Lawrence C. Parish's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lawrence C. Parish accept my insurance?

Dr. Lawrence C. Parish accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 215-563-8333 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Parish's expertise for a condition
ConditionClose
    View All 25 Advanced Conditions
    View All 68 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile